|
業務類別
|
Biotechnology |
|
業務概覽
|
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank. |
| 公司地址
| 2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008 |
| 電話號碼
| +1 442 287-8990 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.lineagecell.com |
| 員工數量
| 77 |
| Mr. Brian M. Culley, M.S. |
Director and Chief Executive Officer |
美元 691.80K |
29/04/2026 |
| Ms. Jill A. Howe |
Chief Financial Officer and Principal Accounting Officer |
美元 467.00K |
29/04/2026 |
| Mr. George A. Samuel, III |
General Counsel and Corporate Secretary |
美元 448.50K |
29/04/2026 |
|
|
| Ms. Deborah Andrews |
Independent Director |
29/04/2026 |
| Mr. Angus Charles Russell |
Independent Director |
29/04/2026 |
| Mr. Brian M. Culley, M.S. |
Director and Chief Executive Officer |
29/04/2026 |
| Mr. Neal C. Bradsher, C.F.A. |
Independent Director |
29/04/2026 |
| Mr. Michael H. Mulroy |
Chairman of the Board |
29/04/2026 |
| Dr. Dipti Mahendra Amin |
Independent Director |
29/04/2026 |
| Dr. Anula Jayasuriya, M.B.A.,M.D.,PhD |
Independent Director |
29/04/2026 |
|
|
|
|
